Insulet Corporation - Common Stock (PODD)
294.00
+16.69 (6.02%)
NASDAQ · Last Trade: Aug 7th, 1:55 PM EDT
Insulet beats Q2 estimates with strong Omnipod growth and lifts 2025 revenue outlook on rising adoption and expanding global customer base.
Via Benzinga · August 7, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · August 7, 2025
Via Benzinga · August 7, 2025
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Via Chartmill · August 7, 2025
The company is still in the early stages of adding patients with type 2 diabetes to its client base.
Via Investor's Business Daily · August 7, 2025
Insulet Corp. (PODD) reported strong Q2 2025 earnings, beating revenue and EPS estimates with $649.1M in sales and $1.17 adjusted EPS. Stock rose 4.58% pre-market. Raised full-year guidance signals growth confidence.
Via Chartmill · August 7, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?
Via Chartmill · August 7, 2025
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Thursday before the bell. Here’s what you need to know.
Via StockStory · August 5, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · July 17, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.
Via StockStory · July 15, 2025
An update on Sana Biotechnology.
Via Benzinga · July 14, 2025
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match.
The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Via StockStory · July 11, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Via StockStory · July 4, 2025
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · July 3, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · July 1, 2025
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process.
Via Investor's Business Daily · July 1, 2025
Via Benzinga · July 1, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via Chartmill · July 1, 2025